How to buy Kadmon stock | $4.34

Kadmon Holdings, Inc is a biotechnology business based in the US. Kadmon shares (KDMN) are listed on the NASDAQ and all prices are listed in US Dollars. Kadmon employs 115 staff and has a trailing 12-month revenue of around USD$12.1 million.

How to buy shares in Kadmon

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Kadmon. Find the stock by name or ticker symbol: KDMN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kadmon reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$4.34, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kadmon, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Kadmon. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Kadmon share price

Use our graph to track the performance of KDMN stocks over time.

Kadmon shares at a glance

• Key figures

Information last updated 2020-12-26.

Latest market close	USD$4.34
52-week range	USD$2.3 - USD$5.5
50-day moving average	USD$4.0718
200-day moving average	USD$4.1587
Wall St. target price	USD$12.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.372

Buy Kadmon shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Kadmon stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Kadmon Holdings, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kadmon price performance over time

Historical closes compared with the close of $4.34 from 2020-12-18

1 week (2021-01-07)	9.60%
1 month (2020-12-17)	-3.13%
3 months (2020-10-15)	5.34%
6 months (2020-07-15)	-0.46%

1 year (2020-01-15)	0.93%
2 years (2019-01-15)	78.60%
3 years (2018-01-13)	N/A
5 years (2016-01-13)	N/A

Kadmon financials

Revenue TTM	USD$12.1 million
Gross profit TTM	USD$3.8 million
Return on assets TTM	-32.37%
Return on equity TTM	-83.78%
Profit margin	0%
Book value	$0.569
Market capitalisation	USD$756.4 million

TTM: trailing 12 months

Shorting Kadmon shares

There are currently 29.5 million Kadmon shares held short by investors – that's known as Kadmon's "short interest". This figure is 4.1% down from 30.7 million last month.

There are a few different ways that this level of interest in shorting Kadmon shares can be evaluated.

Kadmon's "short interest ratio" (SIR)

Kadmon's "short interest ratio" (SIR) is the quantity of Kadmon shares currently shorted divided by the average quantity of Kadmon shares traded daily (recently around 2.5 million). Kadmon's SIR currently stands at 11.71. In other words for every 100,000 Kadmon shares traded daily on the market, roughly 11710 shares are currently held short.

However Kadmon's short interest can also be evaluated against the total number of Kadmon shares, or, against the total number of tradable Kadmon shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kadmon's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Kadmon shares in existence, roughly 160 shares are currently held short) or 0.1614% of the tradable shares (for every 100,000 tradable Kadmon shares, roughly 161 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kadmon.

Find out more about how you can short Kadmon stock.

Kadmon share dividends

We're not expecting Kadmon to pay a dividend over the next 12 months.

Kadmon share price volatility

Over the last 12 months, Kadmon's shares have ranged in value from as little as $2.3 up to $5.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kadmon's is 1.6954. This would suggest that Kadmon's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Kadmon overview

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.

Frequently asked questions

• What percentage of Kadmon is owned by insiders or institutions?

  Currently 0.144% of Kadmon shares are held by insiders and 96.515% by institutions.

• How many people work for Kadmon?

  Latest data suggests 115 work at Kadmon.

• When does the fiscal year end for Kadmon?

  Kadmon's fiscal year ends in December.

• Where is Kadmon based?

  Kadmon's address is: 450 East 29th Street, New York, NY, United States, 10016

• What is Kadmon's ISIN number?

  Kadmon's international securities identification number is: US48283N1063

• What is Kadmon's CUSIP number?

  Kadmon's Committee on Uniform Securities Identification Procedures number is: 48283N106